(ACLX) Arcellx - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 6.700m | Total Return 74.7% in 12m
Stock: Cancer Therapies, Immunotherapies, Drug Development
Total Rating 42
Risk 70
Buy Signal 0.23
| Risk 5d forecast | |
|---|---|
| Volatility | 52.7% |
| Relative Tail Risk | -9.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 47.27 |
| Character TTM | |
|---|---|
| Beta | 1.391 |
| Beta Downside | 1.322 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.44% |
| CAGR/Max DD | 1.10 |
EPS (Earnings per Share)
Revenue
Description: ACLX Arcellx March 05, 2026
Arcellx, Inc. is a biotechnology company developing immunotherapies for cancer and other diseases.
Its primary focus is anitocabtagene autoleucel, a ddCAR product candidate in Phase 2 clinical trials for relapsed or refractory multiple myeloma (rrMM). This is a type of CAR T-cell therapy, a rapidly evolving area in oncology.
Additional pipeline candidates include ACLX-001 (targeting BCMA for rrMM, Phase 1), ARC-SparX programs (Phase 1), and ACLX-002 (targeting CD123 for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Phase 1). The company also has preclinical programs and solid tumor initiatives.
Arcellx operates under a strategic alliance with Kite Pharma, Inc. for the co-development and co-commercialization of anitocabtagene autoleucel. Partnering is a common strategy in biotech for sharing development costs and leveraging commercial expertise.
For more detailed financial and operational data, ValueRay offers comprehensive analytics.
Headlines to watch out for
- Anitocabtagene autoleucel clinical trial results impact future revenue
- Regulatory approval for lead product determines market entry
- Collaboration with Kite Pharma provides development funding
- Pipeline progress in early-stage trials drives investor sentiment
- Competition in CAR-T therapy market affects pricing power
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -228.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -21.57 > 1.0 |
| NWC/Revenue: 1.61k% < 20% (prev 439.1%; Δ 1.17k% < -1%) |
| CFO/TA -0.35 > 3% & CFO -210.3m > Net Income -228.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.3m) vs 12m ago 4.86% < -2% |
| Gross Margin: -72.07% > 18% (prev 0.97%; Δ -7.30k% > 0.5%) |
| Asset Turnover: 3.39% > 50% (prev 15.17%; Δ -11.79% > 0%) |
| Interest Coverage Ratio: -8.45 > 6 (EBITDA TTM -198.0m / Interest Expense TTM 24.2m) |
Altman Z'' -5.89
| A: 0.59 (Total Current Assets 462.2m - Total Current Liabilities 104.2m) / Total Assets 604.0m |
| B: -1.20 (Retained Earnings -725.8m / Total Assets 604.0m) |
| C: -0.31 (EBIT TTM -204.6m / Avg Total Assets 657.7m) |
| D: -3.59 (Book Value of Equity -724.9m / Total Liabilities 201.6m) |
| Altman-Z'' Score: -5.89 = D |
Beneish M
| DSRI: none (Receivables 3.60m/none, Revenue 22.3m/107.9m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.12 (AQ_t 0.12 / AQ_t-1 0.06) |
| SGI: 0.21 (Revenue 22.3m / 107.9m) |
| TATA: -0.03 (NI -228.9m - CFO -210.3m) / TA 604.0m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of ACLX shares?
As of March 30, 2026, the stock is trading at USD 114.57 with a total of 1,648,736 shares traded.
Over the past week, the price has changed by -0.03%, over one month by +0.69%, over three months by +75.91% and over the past year by +74.65%.
Over the past week, the price has changed by -0.03%, over one month by +0.69%, over three months by +75.91% and over the past year by +74.65%.
Is ACLX a buy, sell or hold?
Arcellx has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy ACLX.
- StrongBuy: 12
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111.1 | -3.1% |
| Analysts Target Price | 111.1 | -3.1% |
ACLX Fundamental Data Overview March 29, 2026
P/E Forward = 61.7284
P/S = 300.6386
P/B = 16.6522
Revenue TTM = 22.3m USD
EBIT TTM = -204.6m USD
EBITDA TTM = -198.0m USD
Long Term Debt = 51.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 96.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.35b USD (6.70b + Debt 96.3m - CCE 450.3m)
Interest Coverage Ratio = -8.45 (Ebit TTM -204.6m / Interest Expense TTM 24.2m)
EV/FCF = -29.85x (Enterprise Value 6.35b / FCF TTM -212.6m)
FCF Yield = -3.35% (FCF TTM -212.6m / Enterprise Value 6.35b)
FCF Margin = -953.9% (FCF TTM -212.6m / Revenue TTM 22.3m)
Net Margin = -1.03k% (Net Income TTM -228.9m / Revenue TTM 22.3m)
Gross Margin = -72.07% ((Revenue TTM 22.3m - Cost of Revenue TTM 38.3m) / Revenue TTM)
Gross Margin QoQ = 0.79% (prev none%)
Tobins Q-Ratio = 10.51 (Enterprise Value 6.35b / Total Assets 604.0m)
Interest Expense / Debt = 25.15% (Interest Expense 24.2m / Debt 96.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.7m (EBIT -204.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.44 (Total Current Assets 462.2m / Total Current Liabilities 104.2m)
Debt / Equity = 0.24 (Debt 96.3m / totalStockholderEquity, last quarter 402.4m)
Debt / EBITDA = -0.08 (negative EBITDA) (Net Debt 16.0m / EBITDA -198.0m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 16.0m / FCF TTM -212.6m)
Total Stockholder Equity = 413.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.81% (Net Income -228.9m / Total Assets 604.0m)
RoE = -55.42% (Net Income TTM -228.9m / Total Stockholder Equity 413.1m)
RoCE = -44.01% (EBIT -204.6m / Capital Employed (Equity 413.1m + L.T.Debt 51.9m))
RoIC = -39.14% (negative operating profit) (NOPAT -161.7m / Invested Capital 413.1m)
WACC = 11.01% (E(6.70b)/V(6.80b) * Re(10.88%) + D(96.3m)/V(6.80b) * Rd(25.15%) * (1-Tc(0.21)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.78%
[DCF] Fair Price = unknown (Cash Flow -212.6m)
EPS Correlation: 12.16 | EPS CAGR: 17.90% | SUE: 0.11 | # QB: 0
Revenue Correlation: 44.12 | Revenue CAGR: 27.33% | SUE: -1.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.06 | Chg7d=+0.112 | Chg30d=+0.112 | Revisions Net=+3 | Analysts=3
EPS current Year (2026-12-31): EPS=-4.22 | Chg7d=-0.663 | Chg30d=-0.745 | Revisions Net=+3 | Growth EPS=-3.7% | Growth Revenue=+245.3%
EPS next Year (2027-12-31): EPS=-1.73 | Chg7d=-0.133 | Chg30d=+0.211 | Revisions Net=+0 | Growth EPS=+59.0% | Growth Revenue=+256.0%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)
P/S = 300.6386
P/B = 16.6522
Revenue TTM = 22.3m USD
EBIT TTM = -204.6m USD
EBITDA TTM = -198.0m USD
Long Term Debt = 51.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 96.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.35b USD (6.70b + Debt 96.3m - CCE 450.3m)
Interest Coverage Ratio = -8.45 (Ebit TTM -204.6m / Interest Expense TTM 24.2m)
EV/FCF = -29.85x (Enterprise Value 6.35b / FCF TTM -212.6m)
FCF Yield = -3.35% (FCF TTM -212.6m / Enterprise Value 6.35b)
FCF Margin = -953.9% (FCF TTM -212.6m / Revenue TTM 22.3m)
Net Margin = -1.03k% (Net Income TTM -228.9m / Revenue TTM 22.3m)
Gross Margin = -72.07% ((Revenue TTM 22.3m - Cost of Revenue TTM 38.3m) / Revenue TTM)
Gross Margin QoQ = 0.79% (prev none%)
Tobins Q-Ratio = 10.51 (Enterprise Value 6.35b / Total Assets 604.0m)
Interest Expense / Debt = 25.15% (Interest Expense 24.2m / Debt 96.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.7m (EBIT -204.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.44 (Total Current Assets 462.2m / Total Current Liabilities 104.2m)
Debt / Equity = 0.24 (Debt 96.3m / totalStockholderEquity, last quarter 402.4m)
Debt / EBITDA = -0.08 (negative EBITDA) (Net Debt 16.0m / EBITDA -198.0m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 16.0m / FCF TTM -212.6m)
Total Stockholder Equity = 413.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.81% (Net Income -228.9m / Total Assets 604.0m)
RoE = -55.42% (Net Income TTM -228.9m / Total Stockholder Equity 413.1m)
RoCE = -44.01% (EBIT -204.6m / Capital Employed (Equity 413.1m + L.T.Debt 51.9m))
RoIC = -39.14% (negative operating profit) (NOPAT -161.7m / Invested Capital 413.1m)
WACC = 11.01% (E(6.70b)/V(6.80b) * Re(10.88%) + D(96.3m)/V(6.80b) * Rd(25.15%) * (1-Tc(0.21)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.78%
[DCF] Fair Price = unknown (Cash Flow -212.6m)
EPS Correlation: 12.16 | EPS CAGR: 17.90% | SUE: 0.11 | # QB: 0
Revenue Correlation: 44.12 | Revenue CAGR: 27.33% | SUE: -1.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.06 | Chg7d=+0.112 | Chg30d=+0.112 | Revisions Net=+3 | Analysts=3
EPS current Year (2026-12-31): EPS=-4.22 | Chg7d=-0.663 | Chg30d=-0.745 | Revisions Net=+3 | Growth EPS=-3.7% | Growth Revenue=+245.3%
EPS next Year (2027-12-31): EPS=-1.73 | Chg7d=-0.133 | Chg30d=+0.211 | Revisions Net=+0 | Growth EPS=+59.0% | Growth Revenue=+256.0%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)